SCHEMBL14949126

SCHEMBL14949126

Cc1ccc(F)c(COP)c1

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ IDO1 P14902 2/20 0.40
▸ TAAR1 Q96RJ0 1/20 0.38
▸ HTR2C P28335 3/20 0.37
▸ SLC6A4 P31645 3/20 0.37
▸ HTR2A P28223 2/20 0.34
▸ MAPK1 P28482 1/20 0.34
▸ MAP2K4 P45985 1/20 0.34
▸ MAPKAPK2 P49137 1/20 0.34
▸ MAPKAPK3 Q16644 1/20 0.34
▸ MAPK6 Q16659 1/20 0.34
▸ LMNA P02545 2/20 0.33
▸ MAPT P10636 2/20 0.33
▸ NFE2L2 Q16236 1/20 0.33
▸ HTT P42858 2/20 0.33
▸ TDP1 Q9NUW8 1/20 0.33
▸ AMY1A P0DUB6 1/20 0.32
▸ RXRA P19793 1/20 0.32
▸ GRIN1 Q05586 1/20 0.32
▸ GRIN2B Q13224 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10204881 0.82 TAAR1 (0.39) IDO1TAAR1HTR2CSLC6A4HTR2A
SCHEMBL14949121 0.79 TAAR1 (0.50) TAAR1HTTTDP1
SCHEMBL18213815 0.77 IDO1 (0.38) IDO1TAAR1HTR2CSLC6A4HTR2A
SCHEMBL27479249 0.77 TAAR1 (0.36) IDO1TAAR1HTR2CSLC6A4HTR2A
SCHEMBL3852993 0.77 TAAR1 (0.42) IDO1TAAR1MAPK1MAP2K4MAPKAPK2
SCHEMBL14949127 0.76 FFAR1 (0.43) TAAR1HTR2CSLC6A4HTR2AMAPK1
SCHEMBL13034141 0.74 ALDH1A1 (0.51) LMNA
SCHEMBL8239069 0.74 TAAR1 (0.43) TAAR1MAPK1MAP2K4MAPKAPK2MAPKAPK3
SCHEMBL10290674 0.74 TAAR1 (0.43) TAAR1MAPK1MAP2K4MAPKAPK2MAPKAPK3
SCHEMBL583371 0.72 TAAR1 (0.52) TAAR1SLC6A4HTR2AMAPK1MAP2K4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2776449-B1 PROCESS FOR THE PREPARATION OF BETA-C-ARYL GLUCOSIDES SCINOPHARM TAIWAN LTD (TW) 2017-08-02 — — EP disclosed
US-8952139-B2 Process for the preparation of β-C-aryl glucosides SCINOPHARM TAIWAN, LTD (TW) 2015-02-10 — — US disclosed
US-20140323742-A1 METHODS FOR PREPARING POLYMERIC REAGENTS AND COMPOSITIONS OF POLYMERIC REAGENTS NEKTAR THERAPEUTICS 2014-10-30 — — US disclosed
US-20140128595-A1 Process for the Preparation of ß-C-Aryl Glucosides SCINOPHARM TAIWAN, LTD. (TW) 2014-05-08 — — US disclosed
WO-2013068850-A2 PROCESS FOR THE PREPARATION OF β-C-ARYL GLUCOSIDES SCINOPHARM TAIWAN, LTD. (NA) 2013-05-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140128595-A1 Process for the Preparation of ß-C-Aryl Glucosides SLC5A2, SLC5A1, UGGT1 IDO1 2051/4885TAAR1 4344/4885HTR2C 625/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback